Literature DB >> 25798285

Interstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia.

Xueyan Bai1, Qu Cui1, Yuanbo Liu1.   

Abstract

Rituximab-combined therapeutic regimens have been recommended for treatment of Waldenström's Macroglobulinemia (WM). We report one WM patient who developed interstitial pneumonitis after rituximab therapy.

Entities:  

Keywords:  Interstitial pneumonitis; Waldenström's macroglobulinemia; rituximab; treatment

Year:  2014        PMID： 25798285      PMCID： PMC4352371          DOI： 10.1002/ccr3.152

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN： 2050-0904


  5 in total

1.  Interstitial pneumonitis related to rituximab therapy.

Authors:  Catherine Burton; Richard Kaczmarski; Riaz Jan-Mohamed
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

2.  Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Buske; V Leblond; M Dimopoulos; E Kimby; U Jäger; M Dreyling
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

3.  Fatal interstitial pneumonitis related to rituximab-containing regimen.

Authors:  Yair Herishanu; Aaron Polliack; Leonor Leider-Trejo; Yoel Grieff; Ur Metser; Elizabeth Naparstek
Journal:  Clin Lymphoma Myeloma       Date:  2006-03

Review 4.  Non-infectious pulmonary toxicity of rituximab: a systematic review.

Authors:  Andreas V Hadjinicolaou; Muhammad K Nisar; Helen Parfrey; Edwin R Chilvers; Andrew J K Ostör
Journal:  Rheumatology (Oxford)       Date:  2011-12-07       Impact factor: 7.580

5.  Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.

Authors:  Roger G Owen; Guy Pratt; Rebecca L Auer; Rita Flatley; Charalampia Kyriakou; Michael P Lunn; Francis Matthey; Helen McCarthy; Feargal P McNicholl; Saad M Rassam; Simon D Wagner; Matthew Streetly; Shirley D'Sa
Journal:  Br J Haematol       Date:  2014-02-15       Impact factor: 6.998
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.